Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299).
Crescenzi, Elvira ; Chiaviello, Angela ; Canti, Gianfranco ; et al. ; - ASI Sponsor
Mar - 2006
ISSN : 1535-7163 ;
journal : Molecular cancer therapeutics

Issue : 3
type: Article Journal

Abstract
We compared the effects of monotherapy (photodynamic therapy or chemotherapy) versus combination therapy (photodynamic therapy plus a specific drug) on the non-small cell lung cancer cell line H1299. Our aim was to evaluate whether the additive/synergistic effects of combination treatment were such that the cytostatic dose could be reduced without affecting treatment efficacy. Photodynamic therapy was done by irradiating Photofrin-preloaded H1299 p53/p16-null cells with a halogen lamp equipped with a bandpass filter. The cytotoxic drugs used were cis-diammine-dichloroplatinum [II] (CDDP or cisplatin) and 2,2-difluoro-2-deoxycytidine (gemcitabine). Various treatment combinations yielded therapeutic effects (trypan blue dye exclusion test) ranging from additive to clearly synergistic, the most effective being a combination of photodynamic therapy and CDDP. To gain insight into the cellular response mechanisms underlying favorable outcomes, we analyzed the H1299 cell cycle profiles and the expression patterns of several key proteins after monotherapy. In our conditions, we found that photodynamic therapy with Photofrin targeted G0-G1 cells, thereby causing cells to accumulate in S phase. In contrast, low-dose CDDP killed cells in S phase, thereby causing an accumulation of G0-G1 cells (and increased p21 expression). Like photodynamic therapy, low-dose gemcitabine targeted G0-G1 cells, which caused a massive accumulation of cells in S phase (and increased cyclin A expression). Although we observed therapeutic reinforcement with both drugs and photodynamic therapy, reinforcement was more pronounced when the drug (CDDP) and photodynamic therapy exert disjointed phase-related cytotoxic activity. Thus, if photodynamic therapy is appropriately tuned, the dose of the cytostatic drug can be reduced without compromising the therapeutic response.

keywords : Antineoplastic Agents,Antineoplastic Agents: therapeutic use,Antineoplastic Combined Chemotherapy Protocols,Antineoplastic Combined Chemotherapy Protocols: th,Carcinoma,Cisplatin,Cisplatin: therapeutic use,Deoxycytidine,Deoxycytidine: analogs \& derivatives,Deoxycytidine: therapeutic use,Dihematoporphyrin Ether,Dihematoporphyrin Ether: therapeutic use,Dose-Response Relationship,Drug,G0 Phase,G0 Phase: drug effects,G1 Phase,G1 Phase: drug effects,Humans,Lung Neoplasms,Lung Neoplasms: drug therapy,Lung Neoplasms: pathology,Non-Small-Cell Lung,Non-Small-Cell Lung: drug therapy,Non-Small-Cell Lung: secondary,Photochemotherapy,Photosensitizing Agents,Photosensitizing Agents: therapeutic use